Title :

Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet''s disease: A multicenter observational study of 18 patients.

Author(s) :

Desbois A, C [Auteur]
Biard, Lucie [Auteur]
Addimanda, Olga [Auteur]
Lambert, Marc [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Launay, David [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Ackermann, Felix [Auteur]
Perard, Laurent [Auteur]
Hot, Arnaud [Auteur]
Maurier, Francois [Auteur]
Mausservey, C [Auteur]
Bernard, F [Auteur]
Noel, N [Auteur]
Alric, Laurent [Auteur]
Mirault, Tristan [Auteur]
Cohen, Fleur [Auteur]
Boussouar, S [Auteur]
Resche-Rigon, Matthieu [Auteur]
Cacoub, Patrice [Auteur]
Saadoun, David [Auteur]

Journal title :

Clinical immunology (Orlando, Fla.)

Abbreviated title :

Clin. Immunol.

Publication date :

2018-08-17

ISSN :

1521-7035

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: To describe the outcome and tolerance in patients treated with anti-TNFalpha in severe and refractory major vessel disease in Behcet's disease (BD). METHODS: A multicenter study evaluating 18 refractory BD ...
Show more >OBJECTIVE: To describe the outcome and tolerance in patients treated with anti-TNFalpha in severe and refractory major vessel disease in Behcet's disease (BD). METHODS: A multicenter study evaluating 18 refractory BD patients with major vessel involvement [pulmonary artery (n=4), aorta (n=4) or peripheral artery aneurysm (n=1) and/or pulmonary artery (n=7), inferior vena cava (n=5), or intra-cardiac (n=3) thrombosis or Budd Chiari Syndrome (n=2)] treated with anti-TNFalpha agents. RESULTS: Vascular remission was achieved in 16 (89%) patients. The 9months risk of relapse was significantly higher with conventional immunosuppressants used prior anti-TNFalpha agents as compared to anti-TNFalpha therapy [OR=8.7 (1.42-62.6), p=0.03]. The median daily dose of corticosteroids significantly decreased at 12months. Side effects included infection (n=4) and pulmonary edema (n=1). CONCLUSION: TNFalpha-antagonists are safe and might be associated with a decreased risk of relapse at 9months compared to conventional immunosuppressants in BD patients with major vessels disease.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Immunity, inflammation and fibrsis in auto and allo-reactivity
Glycation from inflammation to aging

Submission date :

2019-03-01T14:17:40Z